CR10478A - Amino-piperidine derivatives as cetp inhibitors - Google Patents
Amino-piperidine derivatives as cetp inhibitorsInfo
- Publication number
- CR10478A CR10478A CR10478A CR10478A CR10478A CR 10478 A CR10478 A CR 10478A CR 10478 A CR10478 A CR 10478A CR 10478 A CR10478 A CR 10478A CR 10478 A CR10478 A CR 10478A
- Authority
- CR
- Costa Rica
- Prior art keywords
- amino
- piperidine derivatives
- cetp inhibitors
- cetp
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06117541 | 2006-07-20 | ||
| US88705807P | 2007-01-29 | 2007-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR10478A true CR10478A (es) | 2009-02-02 |
Family
ID=38695303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR10478A CR10478A (es) | 2006-07-20 | 2008-12-02 | Amino-piperidine derivatives as cetp inhibitors |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20090286790A1 (es) |
| EP (1) | EP2049517B1 (es) |
| JP (1) | JP5042311B2 (es) |
| KR (1) | KR101149274B1 (es) |
| AR (1) | AR061926A1 (es) |
| AU (1) | AU2007276433B2 (es) |
| CA (1) | CA2657258A1 (es) |
| CL (1) | CL2007002107A1 (es) |
| CO (1) | CO6150155A2 (es) |
| CR (1) | CR10478A (es) |
| EC (1) | ECSP099078A (es) |
| GT (1) | GT200900010A (es) |
| HK (1) | HK1132262A1 (es) |
| HR (1) | HRP20140183T1 (es) |
| IL (1) | IL195792A (es) |
| MA (1) | MA30638B1 (es) |
| MX (1) | MX2009000646A (es) |
| NO (1) | NO342106B1 (es) |
| PE (1) | PE20080404A1 (es) |
| PL (1) | PL2049517T3 (es) |
| TN (1) | TN2009000012A1 (es) |
| TW (1) | TWI387593B (es) |
| WO (1) | WO2008009435A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2696016A1 (en) * | 2007-07-13 | 2009-01-22 | Addex Pharma S.A. | Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CN101910150B (zh) | 2007-11-05 | 2013-09-18 | 诺瓦提斯公司 | 作为cetp抑制剂、可用于治疗疾病如高脂血症或动脉硬化的4-苄基氨基-1-羧基酰基哌啶衍生物 |
| ES2375527T3 (es) * | 2007-12-03 | 2012-03-01 | Novartis Ag | Derivados 1,2-disustituidos-4-bencilamino-pirrolidina como inhibidores cetp útiles para el tratamiento de enfermedades tales como hiperlipidemia o arteriosclerosis. |
| EP2231601B1 (en) | 2007-12-12 | 2014-06-18 | Amgen Inc. | Glycine transporter-1 inhibitors |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| CN103221405B (zh) | 2010-07-09 | 2015-04-22 | 第一三共株式会社 | 取代的吡啶化合物 |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| MX2014000342A (es) * | 2011-07-08 | 2014-05-01 | Novartis Ag | Metodo para tratar la aterosclerosis en sujetos con alto nivel de trigliceridos. |
| TWI570118B (zh) | 2012-01-06 | 2017-02-11 | 第一三共股份有限公司 | 經取代之吡啶化合物的酸加成鹽 |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| KR20150119109A (ko) | 2013-02-14 | 2015-10-23 | 노파르티스 아게 | Nep (중성 엔도펩티다제) 억제제로서의 치환된 비스페닐 부타노익 포스폰산 유도체 |
| JP2014172851A (ja) * | 2013-03-07 | 2014-09-22 | Chiba Univ | ピラゾール誘導体の製造方法およびイソオキサゾール誘導体の製造方法 |
| KR20160031552A (ko) | 2013-07-25 | 2016-03-22 | 노파르티스 아게 | 합성 아펠린 폴리펩티드의 생체접합체 |
| TN2016000031A1 (en) | 2013-07-25 | 2017-07-05 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
| JP6402907B2 (ja) * | 2014-09-24 | 2018-10-10 | Jnc株式会社 | ピペリジン誘導体、液晶組成物および液晶表示素子 |
| CU20170093A7 (es) | 2015-01-23 | 2017-09-06 | Novartis Ag | Conjugados de ácidos grasos y apelina sintética con mayor vida media |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| CR20220066A (es) | 2019-08-14 | 2022-11-28 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 |
| CN110508018B (zh) * | 2019-09-03 | 2022-02-25 | 中国石油大学(华东) | 生产聚甲氧基二甲醚的装置及方法 |
| PE20221905A1 (es) | 2019-10-11 | 2022-12-23 | Incyte Corp | Aminas biciclicas como inhibidoras de la cdk2 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
| US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
| RU2086544C1 (ru) | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
| MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| TW313568B (es) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
| US6140342A (en) * | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
| CA2345103C (en) | 1998-09-25 | 2011-04-26 | Monsanto Company | (r)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity |
| ES2377318T3 (es) | 2002-09-06 | 2012-03-26 | Cerulean Pharma Inc. | Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos |
| EP1718309A2 (en) | 2004-01-30 | 2006-11-08 | Japan Tobacco, Inc. | Anorectic compounds |
| MY150958A (en) * | 2005-06-16 | 2014-03-31 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
| ES2375527T3 (es) * | 2007-12-03 | 2012-03-01 | Novartis Ag | Derivados 1,2-disustituidos-4-bencilamino-pirrolidina como inhibidores cetp útiles para el tratamiento de enfermedades tales como hiperlipidemia o arteriosclerosis. |
-
2007
- 2007-07-18 KR KR1020097001089A patent/KR101149274B1/ko not_active IP Right Cessation
- 2007-07-18 WO PCT/EP2007/006384 patent/WO2008009435A1/en active Application Filing
- 2007-07-18 AR ARP070103209A patent/AR061926A1/es unknown
- 2007-07-18 AU AU2007276433A patent/AU2007276433B2/en not_active Ceased
- 2007-07-18 PL PL07786158T patent/PL2049517T3/pl unknown
- 2007-07-18 CA CA002657258A patent/CA2657258A1/en not_active Abandoned
- 2007-07-18 JP JP2009519868A patent/JP5042311B2/ja not_active Expired - Fee Related
- 2007-07-18 MX MX2009000646A patent/MX2009000646A/es active IP Right Grant
- 2007-07-18 US US12/374,463 patent/US20090286790A1/en not_active Abandoned
- 2007-07-18 EP EP07786158.1A patent/EP2049517B1/en active Active
- 2007-07-19 TW TW096126359A patent/TWI387593B/zh not_active IP Right Cessation
- 2007-07-19 CL CL200702107A patent/CL2007002107A1/es unknown
- 2007-07-19 PE PE2007000936A patent/PE20080404A1/es not_active Application Discontinuation
-
2008
- 2008-12-02 CR CR10478A patent/CR10478A/es unknown
- 2008-12-08 IL IL195792A patent/IL195792A/en active IP Right Grant
-
2009
- 2009-01-16 GT GT200900010A patent/GT200900010A/es unknown
- 2009-01-16 TN TN2009000012A patent/TN2009000012A1/fr unknown
- 2009-01-19 EC EC2009009078A patent/ECSP099078A/es unknown
- 2009-01-20 CO CO09004534A patent/CO6150155A2/es unknown
- 2009-02-11 MA MA31630A patent/MA30638B1/fr unknown
- 2009-02-17 NO NO20090756A patent/NO342106B1/no not_active IP Right Cessation
- 2009-10-20 HK HK09109684.3A patent/HK1132262A1/xx not_active IP Right Cessation
-
2014
- 2014-02-27 HR HRP20140183TT patent/HRP20140183T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO342106B1 (no) | 2018-03-26 |
| EP2049517B1 (en) | 2013-11-27 |
| US20090286790A1 (en) | 2009-11-19 |
| GT200900010A (es) | 2009-06-24 |
| TN2009000012A1 (en) | 2010-08-19 |
| KR101149274B1 (ko) | 2012-05-29 |
| JP5042311B2 (ja) | 2012-10-03 |
| PL2049517T3 (pl) | 2014-06-30 |
| IL195792A0 (en) | 2009-09-01 |
| HK1132262A1 (en) | 2010-02-19 |
| EP2049517A1 (en) | 2009-04-22 |
| WO2008009435A1 (en) | 2008-01-24 |
| IL195792A (en) | 2013-07-31 |
| AR061926A1 (es) | 2008-10-01 |
| TWI387593B (zh) | 2013-03-01 |
| MA30638B1 (fr) | 2009-08-03 |
| HRP20140183T1 (hr) | 2014-04-11 |
| CL2007002107A1 (es) | 2008-06-06 |
| ECSP099078A (es) | 2009-02-27 |
| CO6150155A2 (es) | 2010-04-20 |
| AU2007276433A1 (en) | 2008-01-24 |
| TW200813022A (en) | 2008-03-16 |
| CA2657258A1 (en) | 2008-01-24 |
| MX2009000646A (es) | 2009-01-29 |
| NO20090756L (no) | 2009-04-14 |
| PE20080404A1 (es) | 2008-06-27 |
| JP2009543827A (ja) | 2009-12-10 |
| AU2007276433B2 (en) | 2011-06-16 |
| KR20090031579A (ko) | 2009-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR10478A (es) | Amino-piperidine derivatives as cetp inhibitors | |
| CY2020023I1 (el) | Αναστολεiς βητα-λακταμασων | |
| CY2017016I1 (el) | Αναστολεις πρωτεασωματος | |
| DK2041138T3 (da) | Pyrroltriazinkinase-inhibitorer | |
| DK2024375T3 (da) | Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere | |
| CR10831A (es) | INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA | |
| DK2016080T3 (da) | Dihydropyrazolopyrimidinon-derivater | |
| ATE483711T1 (de) | Spiroindolinonderivate | |
| ATE469905T1 (de) | Pyridopyrimidinonderivate | |
| ATE512135T1 (de) | Spiroindolinonderivate | |
| DK2035394T3 (da) | 2-pyrazincarboxamidderivater | |
| BRPI0716781A2 (pt) | Inibidores da quinase | |
| DK2402317T3 (da) | DGAT-inhibitor | |
| BRPI0810374A2 (pt) | Inibidores específicos do pdgfrbeta | |
| DK2086939T3 (da) | Pyridiacarboxamid som II-beta-HSDI-inhibitorer | |
| ATE488505T1 (de) | Kinasehemmer auf hydantoinbasis | |
| ATE506358T1 (de) | 2-benzylpyridazinonderivate als met-kinasehemmer | |
| ATE467623T1 (de) | Diazepan-acetamidderivate als selektive 11-hsd1- hemmer | |
| NO20085127L (no) | Leptomycinderivater | |
| BRPI0918564A2 (pt) | inibidores | |
| CR10879A (es) | Cyclized derivatives as eg-5 inhibitors | |
| BRPI0720547A2 (pt) | Inibidores de metaloprotease derivada de heterocíclico | |
| ATE544764T1 (de) | 5-hydroxymethyloxazolidin-2-onderivate | |
| DK2046802T3 (da) | 2-substituerede methylpenamderivater | |
| DK2066662T3 (da) | Serinhydrolaseinhibitorer |